Editing Clinical Trials (section)

=== Pembrolizumab Plus Chemotherapy — FDA Approved September 2024 ===

The KEYNOTE-483 trial led to FDA approval for first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma on September 17, 2024.<ref>[https://www.mesotheliomalawyercenter.org/mesothelioma/prognosis/ Mesothelioma Prognosis], Mesothelioma Lawyer Center</ref>

'''Trial Results:'''
* '''Median overall survival:''' 16.9 months versus 14.1 months with chemotherapy alone
* '''Hazard ratio:''' 0.79 (95% CI: 0.63-0.99; p=0.0209)
* '''Confirmed objective response rate:''' 52% versus 29%
* '''Median duration of response:''' 6.9 versus 6.8 months
* '''Regimen:''' Pembrolizumab with pemetrexed and platinum chemotherapy

'''January 2026 Update:''' FDA approved Keytruda QLEX (subcutaneous pembrolizumab) on January 11, 2026, offering a 1-minute injection every 3 weeks as an alternative to IV infusion for all 38 pembrolizumab indications including mesothelioma.